China NT Pharma Group Company Limited (HKG:1011)
Hong Kong
· Delayed Price · Currency is HKD 0.4200
+0.0200 (5.00%)
Jun 30, 2025, 1:54 PM HKT
HKG:1011 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 37.96 | 7.37 | - | 226.7 | 221.73 | Upgrade
| |
Revenue Growth (YoY) | 415.34% | - | - | 2.24% | 44.48% | Upgrade
|
Cost of Revenue | 32.7 | - | - | 81.24 | 86.83 | Upgrade
|
Gross Profit | 5.26 | 7.37 | - | 145.46 | 134.9 | Upgrade
|
Selling, General & Admin | 18.49 | 63.57 | 22.62 | 229.19 | 219.33 | Upgrade
|
Other Operating Expenses | - | - | - | - | -10.01 | Upgrade
|
Operating Expenses | 18.49 | 63.57 | 26.54 | 238.93 | 207.93 | Upgrade
|
Operating Income | -13.23 | -56.21 | -26.54 | -93.47 | -73.03 | Upgrade
|
Interest Expense | -31.54 | -28.82 | -39.37 | -88.73 | -85.11 | Upgrade
|
Interest & Investment Income | 0.01 | 0.01 | 0.04 | 0.24 | 2.84 | Upgrade
|
Earnings From Equity Investments | 10.24 | 37.04 | 9 | 34.49 | 0.01 | Upgrade
|
Currency Exchange Gain (Loss) | - | - | - | 6.66 | 16.13 | Upgrade
|
Other Non Operating Income (Expenses) | -6.06 | 0.26 | 0.5 | 6.5 | -70.13 | Upgrade
|
EBT Excluding Unusual Items | -40.58 | -47.71 | -56.37 | -134.32 | -209.3 | Upgrade
|
Merger & Restructuring Charges | - | - | - | -1.4 | - | Upgrade
|
Gain (Loss) on Sale of Investments | -5.92 | - | -0.63 | -6.04 | - | Upgrade
|
Gain (Loss) on Sale of Assets | -7.01 | 12.29 | - | 41.04 | 0.3 | Upgrade
|
Asset Writedown | - | - | - | - | 10.98 | Upgrade
|
Legal Settlements | - | - | - | -40.63 | -2.27 | Upgrade
|
Other Unusual Items | 0.03 | 2.05 | 6.95 | -7.4 | - | Upgrade
|
Pretax Income | -53.48 | -33.37 | -50.04 | -148.75 | -200.29 | Upgrade
|
Income Tax Expense | -0.12 | 0.12 | - | 2.58 | -9.02 | Upgrade
|
Earnings From Continuing Operations | -53.36 | -33.49 | -50.04 | -151.33 | -191.27 | Upgrade
|
Earnings From Discontinued Operations | - | -110.1 | -16.37 | - | -168.64 | Upgrade
|
Net Income to Company | -53.36 | -143.59 | -66.41 | -151.33 | -359.91 | Upgrade
|
Minority Interest in Earnings | - | - | - | 1.8 | 2.31 | Upgrade
|
Net Income | -53.36 | -143.59 | -66.41 | -149.54 | -357.6 | Upgrade
|
Net Income to Common | -53.36 | -143.59 | -66.41 | -149.54 | -357.6 | Upgrade
|
Shares Outstanding (Basic) | 264 | 239 | 190 | 189 | 189 | Upgrade
|
Shares Outstanding (Diluted) | 264 | 239 | 190 | 189 | 189 | Upgrade
|
Shares Change (YoY) | 10.72% | 25.59% | 0.51% | 0.14% | 6.98% | Upgrade
|
EPS (Basic) | -0.20 | -0.60 | -0.35 | -0.79 | -1.90 | Upgrade
|
EPS (Diluted) | -0.20 | -0.60 | -0.35 | -0.79 | -1.90 | Upgrade
|
Free Cash Flow | -9.24 | 39.74 | 31.72 | -135.98 | 2.36 | Upgrade
|
Free Cash Flow Per Share | -0.04 | 0.17 | 0.17 | -0.72 | 0.01 | Upgrade
|
Gross Margin | 13.86% | 100.00% | - | 64.16% | 60.84% | Upgrade
|
Operating Margin | -34.84% | -763.07% | - | -41.23% | -32.93% | Upgrade
|
Profit Margin | -140.56% | -1949.36% | - | -65.96% | -161.28% | Upgrade
|
Free Cash Flow Margin | -24.35% | 539.55% | - | -59.98% | 1.06% | Upgrade
|
EBITDA | -13.18 | -51.63 | -9.39 | -57.27 | -52.76 | Upgrade
|
EBITDA Margin | -34.72% | - | - | -25.26% | -23.79% | Upgrade
|
D&A For EBITDA | 0.05 | 4.58 | 17.16 | 36.2 | 20.27 | Upgrade
|
EBIT | -13.23 | -56.21 | -26.54 | -93.47 | -73.03 | Upgrade
|
EBIT Margin | -34.84% | - | - | -41.23% | -32.93% | Upgrade
|
Advertising Expenses | - | - | - | 141.48 | - | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.